Every digest is drafted from a single cited abstract or trial record. Each claim in it had to match a verbatim quote from that record before publishing, and doses appear only as the study reported them. See the editorial policy.
In male diet-induced obese rats, indirect calorimetry over 6 weeks of CagriSema treatment and 4 weeks after discontinuation showed weight loss attributed mainly to lower energy intake, with rapid regain once treatment stopped.
A narrative review in The Journal of the American Academy of Orthopaedic Surgeons searched three databases through June 2026 and reports that direct musculoskeletal evidence for BPC-157 is predominantly small-animal work, with human data limited to one uncontrolled case series.
A narrative review in Pharmaceuticals surveys cytoprotective approaches to liver injury, comparing BPC 157 with agents such as N-acetylcysteine and melatonin, and states that experimental evidence does not establish clinical efficacy.
A systematic review and Bayesian meta-analysis of six randomized trials in people with type 2 diabetes reports large HbA1c and body-weight differences versus placebo, with a smaller and uncertain HbA1c advantage over dose-matched semaglutide.
A Cureus narrative review of incretin-based obesity drugs in adults with overweight or obesity names CagriSema among emerging combination therapies and states that long-term efficacy and safety data remain limited.
A systematic review and meta-analysis of five randomised trials in 4,746 adults reports a 6.89 percentage-point greater weight reduction with CagriSema than semaglutide 2.4 mg, with more frequent injection-site reactions.
A narrative review of regenerative peptides including BPC-157 presents three uncontrolled clinical cases of inferior alveolar nerve injury managed with peptides, dexamethasone and local anesthetic; the authors report neurosensory recovery but state causality cannot be established.
A PRISMA-compliant systematic review identified three human studies of BPC-157 totalling 30 participants. All reported symptom improvement without treatment-related adverse events, but were judged poor quality with very low certainty of evidence.
A scoping review of 42 articles representing 41 unique studies in people with overweight or obesity summarized anti-obesity medications, reporting the largest weight-loss figures for incretin-based drugs.
A narrative review searching three databases through June 2026 summarizes trial results for zenagamtide, eloralintide and CagriSema, reporting weight loss up to 22.7% and HbA1c reduction up to 2.0% for CagriSema.
A narrative review in the Indian Journal of Pharmacology surveys approved obesity drugs and lists CagriSema among emerging dual and triple combinations. The abstract reports no new patient data and no dosing.
A preclinical study in diet-induced obese male rats reports that daily co-administration of the amylin analogue cagrilintide with the tri-agonist retatrutide lowered body weight and food intake more than either drug alone.
A narrative expert review synthesizing randomized trials, observational studies, meta-analyses, and pharmacovigilance data reports nausea, vomiting, diarrhea, and constipation in roughly 30%-50% of patients on GLP-1-based therapies.
A ClinicalTrials.gov registration describes a randomized comparison of two cagrilintide versions, B and D, each given as a once-weekly subcutaneous injection for 5 weeks, with participation lasting about 14 weeks.
A narrative review in Missouri Medicine groups BPC-157 with TB-500, melanotan-II and other non-prescription injectables, stating these substances lack established human safety profiles and outlining categories of potential toxicity.
A ClinicalTrials.gov registration describes a randomized, blinded study comparing CagriSema with semaglutide alone, cagrilintide alone and placebo in people with chronic kidney disease, type 2 diabetes and overweight or obesity over about 35 weeks.
A ClinicalTrials.gov registration describes a two-part phase 1 trial in 80 people comparing subcutaneous CagriSema with a calorie-reduced diet, then giving CagriSema to all participants. No outcomes are posted.
A design and baseline-characteristics paper for REDEFINE 3, a double-blind, randomized, placebo-controlled trial of CagriSema in adults with cardiovascular disease and excess adiposity. No outcome results are reported.
A completed phase 3 ClinicalTrials.gov registration describes once-weekly subcutaneous CagriSema versus matched placebo in 274 people with type 2 diabetes treated with basal insulin, with no results posted in this record.
A trial registration states that participants with obesity, with or without type 2 diabetes, will be assigned by chance to CagriSema at one of two dose levels or to semaglutide, each given once weekly by subcutaneous injection for 72 weeks.